Novo Nordisk partners with Anthropic to accelerate drug discovery via AI

Novo Nordisk has entered a collaboration with Anthropic to integrate artificial intelligence into its pharmaceutical research and development processes. The partnership focuses on using Anthropic’s Claude Science platform to accelerate drug discovery, support biological reasoning, and address specific scientific challenges identified by Novo’s researchers.

Beyond drug discovery, Novo Nordisk intends to use Anthropic’s models to enhance its internal AI-driven software development. The company aims to become the world’s most AI-driven healthcare company, utilizing these tools to compress the timeline from initial research to the marketing of new treatments.

The collaboration will operate under strict data governance and human oversight to ensure compliance with ethical and regulatory standards. This initiative follows previous AI-related partnerships between Novo Nordisk and other major technology firms, including OpenAI and Amazon Web Services.